「英克司兰优先」策略对比常规治疗在动脉粥样硬化性心血管病患者中的效果
VICTORION-INITIATE 试验将 450 例动脉粥样硬化性心血管病患者随机分为「英克司兰优先」策略组(最大耐受他汀未达 LDL-C<70 mg/dL 时立即加用英克司兰 284 mg,第 0、90、270 天)与常规治疗组。第 330 天时,「英克司兰优先」组 LDL-C 降幅显著大于常规治疗(60.0% vs 7.0%,P<0.001),且未增加他汀停药或新的安全性问题。
要点
- 「英克司兰优先」策略较常规治疗显著降低 LDL-C(60.0% vs 7.0%)
- 他汀停药率非劣于常规治疗(6.0% vs 16.7%)
- LDL-C<70 mg/dL 达标率 81.8% vs 22.2%,<55 mg/dL 为 71.6% vs 8.9%
核心结论
- 「英克司兰优先」策略较常规治疗带来更大幅度的 LDL-C 降低,且不 discouraging 他汀使用或增加新的安全性担忧。
研究设计与样本
- VICTORION-INITIATE 为前瞻性、实用性设计的随机、多中心、开放标签试验,纳入 450 例动脉粥样硬化性心血管病患者。
- 患者按 1:1 随机接受英克司兰(284 mg 第 0、90、270 天)联合常规治疗(降脂管理由主治医生决定)或单纯常规治疗。
- 主要终点为 LDL-C 自基线的百分比变化及他汀停药率。
主要发现
- 「英克司兰优先」策略组 LDL-C 自基线至第 330 天降幅显著大于常规治疗(60.0% vs 7.0%,P<0.001)。
- 「英克司兰优先」组他汀停药率 6.0%,非劣于常规治疗组的 16.7%。
- 「英克司兰优先」组更多患者达到 LDL-C 目标(<70 mg/dL:81.8% vs 22.2%;<55 mg/dL:71.6% vs 8.9%;P<0.001)。
- 治疗中出现的不良事件(TEAE)和严重 TEAE 发生率在两组间相近(62.8% vs 53.7% 和 11.5% vs 13.4%)。
- 注射部位 TEAE 和导致停药 TEAE 在「英克司兰优先」组更常见(10.3% vs 0.0% 和 2.6% vs 0.0%)。
关键数值与推荐
- 「英克司兰优先」策略定义为最大耐受他汀治疗下 LDL-C 仍未达标(<70 mg/dL)时立即加用英克司兰。
- 英克司兰给药方案为 284 mg 于第 0、90、270 天皮下注射。
- 基线平均 LDL-C 为 97.4 mg/dL;女性占 30.9%,黑人占 12.4%,西班牙裔占 15.3%。
临床怎么用
- 对于最大耐受他汀治疗后 LDL-C 仍≥70 mg/dL 的动脉粥样硬化性心血管病患者,可考虑早期加用英克司兰以大幅提高达标率。
- 该策略不增加他汀停药,但需注意注射部位不良反应及因不良反应停药的风险。
局限性
- 原文未报告
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Most patients with atherosclerotic cardiovascular disease fail to achieve guideline-directed low-density lipoprotein cholesterol (LDL-C) goals. Twice-yearly inclisiran lowers LDL-C by ∼50% when added to statins. OBJECTIVES: This study evaluated the effectiveness of an "inclisiran first" implementation strategy (adding inclisiran immediately upon failure to reach LDL-C <70 mg/dL despite receiving maximally tolerated statins) vs representative usual care in U.S. patients with atherosclerotic cardiovascular disease. METHODS: VICTORION-INITIATE, a prospective, pragmatically designed trial, randomized patients 1:1 to inclisiran (284 mg at days 0, 90, and 270) plus usual care (lipid management at treating physician's discretion) vs usual care alone. Primary endpoints were percentage change in LDL-C from baseline and statin discontinuation rates. RESULTS: We randomized 450 patients (30.9% women, 12.4% Black, 15.3% Hispanic); mean baseline LDL-C was 97.4 mg/dL. The "inclisiran first" strategy led to significantly greater reductions in LDL-C from baseline to day 330 vs usual care (60.0% vs 7.0%; P < 0.001). Statin discontinuation rates with "inclisiran first" (6.0%) were noninferior vs usual care (16.7%). More "inclisiran first" patients achieved LDL-C goals vs usual care (<70 mg/dL: 81.8% vs 22.2%; <55 mg/dL: 71.6% vs 8.9%; P < 0.001). Treatment-emergent adverse event (TEAE) and serious TEAE rates compared similarly between treatment strategies (62.8% vs 53.7% and 11.5% vs 13.4%, respectively). Injection-site TEAEs and TEAEs causing treatment withdrawal occurred more commonly with "inclisiran first" than usual care (10.3% vs 0.0% and 2.6% vs 0.0%, respectively). CONCLUSIONS: An "inclisiran first" implementation strategy led to greater LDL-C lowering compared with usual care without discouraging statin use or raising new safety concerns. (A Randomized, Multicenter, Open-label Trial Comparing the Effectiveness of an "Inclisiran First" Implementation Strategy to Usual Care on LDL Cholesterol [LDL-C] in Patients With Atherosclerotic Cardiovascular Disease and Elevated LDL-C [≥70 mg/dL] Despite Receiving Maximally Tolerated Statin Therapy [VICTORION-INITIATE]; NCT04929249).
引用
- Koren MJ, Rodriguez F, East C, et al. An "Inclisiran First" Strategy vs Usual Care in Patients With Atherosclerotic Cardiovascular Disease. J Am Coll Cardiol. 2024. PMID: 38593947. doi:10.1016/j.jacc.2024.03.382
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。